In sum, our findings implicated that inhibiting Akt signaling represents a potential therapeutic modality to target tumor progression in PTC patients who present with aggressive disease and elevated PI3K/Akt signaling pathway activity. This evidence concerns the gene AKT1 and neoplasm.